<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>S Le Bihan on Raunak Shrestha</title>
    <link>/authors/s-le-bihan/</link>
    <description>Recent content in S Le Bihan on Raunak Shrestha</description>
    <generator>Source Themes academia (https://sourcethemes.com/academic/)</generator>
    <language>en-us</language>
    <copyright>Copyright &amp;copy; {year} Raunak Shrestha</copyright>
    <lastBuildDate>Thu, 14 Jan 2021 00:00:00 +0000</lastBuildDate>
    
	    <atom:link href="/authors/s-le-bihan/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>Multiomics Characterization of Low-grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK-inhibitor Sensitivity and Therapeutic Vulnerability</title>
      <link>/publication/2021_lgsoc/</link>
      <pubDate>Thu, 14 Jan 2021 00:00:00 +0000</pubDate>
      
      <guid>/publication/2021_lgsoc/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Well-Differentiated Papillary Mesothelioma of the Peritoneum is Genetically Distinct from Malignant Mesothelioma</title>
      <link>/publication/2020_wdpm/</link>
      <pubDate>Sat, 13 Jun 2020 00:00:00 +0000</pubDate>
      
      <guid>/publication/2020_wdpm/</guid>
      <description>&lt;blockquote class=&#34;twitter-tweet&#34;&gt;&lt;p lang=&#34;en&#34; dir=&#34;ltr&#34;&gt;Happy to share our paper published today on genomic characterization of a rare form of a very rare cancer, Well-Differentiated Papillary Mesothelioma (WDPM) of the Peritoneum &lt;a href=&#34;https://t.co/khLK683Y4P&#34;&gt;https://t.co/khLK683Y4P&lt;/a&gt; &lt;a href=&#34;https://twitter.com/hashtag/mesothelioma?src=hash&amp;amp;ref_src=twsrc%5Etfw&#34;&gt;#mesothelioma&lt;/a&gt; &lt;a href=&#34;https://twitter.com/hashtag/PeritonealMesothelioma?src=hash&amp;amp;ref_src=twsrc%5Etfw&#34;&gt;#PeritonealMesothelioma&lt;/a&gt; &lt;a href=&#34;https://twitter.com/hashtag/WDPM?src=hash&amp;amp;ref_src=twsrc%5Etfw&#34;&gt;#WDPM&lt;/a&gt; &lt;a href=&#34;https://twitter.com/Cancers_MDPI?ref_src=twsrc%5Etfw&#34;&gt;@Cancers_MDPI&lt;/a&gt; &lt;a href=&#34;https://t.co/7pvE42nLTo&#34;&gt;pic.twitter.com/7pvE42nLTo&lt;/a&gt;&lt;/p&gt;&amp;mdash; Raunak Shrestha (@raunakms) &lt;a href=&#34;https://twitter.com/raunakms/status/1271945447666413568?ref_src=twsrc%5Etfw&#34;&gt;June 13, 2020&lt;/a&gt;&lt;/blockquote&gt; &lt;script async src=&#34;https://platform.twitter.com/widgets.js&#34; charset=&#34;utf-8&#34;&gt;&lt;/script&gt;
</description>
    </item>
    
    <item>
      <title>BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma</title>
      <link>/publication/2019_mesothelioma/</link>
      <pubDate>Thu, 07 Feb 2019 00:00:00 +0000</pubDate>
      
      <guid>/publication/2019_mesothelioma/</guid>
      <description>&lt;blockquote class=&#34;twitter-tweet&#34; data-lang=&#34;en&#34;&gt;&lt;p lang=&#34;en&#34; dir=&#34;ltr&#34;&gt;Our paper describing a potentially new treatment for Peritoneal &lt;a href=&#34;https://twitter.com/hashtag/Mesothelioma?src=hash&amp;amp;ref_src=twsrc%5Etfw&#34;&gt;#Mesothelioma&lt;/a&gt; published today in &lt;a href=&#34;https://twitter.com/GenomeMedicine?ref_src=twsrc%5Etfw&#34;&gt;@GenomeMedicine&lt;/a&gt;  &lt;a href=&#34;https://t.co/admejVvX5K&#34;&gt;https://t.co/admejVvX5K&lt;/a&gt; &lt;a href=&#34;https://twitter.com/VanProstateCtr?ref_src=twsrc%5Etfw&#34;&gt;@VanProstateCtr&lt;/a&gt; &lt;a href=&#34;https://twitter.com/hashtag/PrecisionOncology?src=hash&amp;amp;ref_src=twsrc%5Etfw&#34;&gt;#PrecisionOncology&lt;/a&gt; &lt;a href=&#34;https://twitter.com/hashtag/Immunotherapy?src=hash&amp;amp;ref_src=twsrc%5Etfw&#34;&gt;#Immunotherapy&lt;/a&gt; &lt;a href=&#34;https://twitter.com/hashtag/Cancer?src=hash&amp;amp;ref_src=twsrc%5Etfw&#34;&gt;#Cancer&lt;/a&gt; &lt;a href=&#34;https://twitter.com/hashtag/Genomics?src=hash&amp;amp;ref_src=twsrc%5Etfw&#34;&gt;#Genomics&lt;/a&gt; (1/n) &lt;a href=&#34;https://t.co/mWrsjpTsr1&#34;&gt;pic.twitter.com/mWrsjpTsr1&lt;/a&gt;&lt;/p&gt;&amp;mdash; Raunak Shrestha (@raunakms) &lt;a href=&#34;https://twitter.com/raunakms/status/1097516525865431041?ref_src=twsrc%5Etfw&#34;&gt;February 18, 2019&lt;/a&gt;&lt;/blockquote&gt;
&lt;script async src=&#34;https://platform.twitter.com/widgets.js&#34; charset=&#34;utf-8&#34;&gt;&lt;/script&gt;
&lt;blockquote class=&#34;twitter-tweet&#34; data-lang=&#34;en&#34;&gt;&lt;p lang=&#34;en&#34; dir=&#34;ltr&#34;&gt;Great to see our work ( &lt;a href=&#34;https://t.co/admejVvX5K&#34;&gt;https://t.co/admejVvX5K&lt;/a&gt; ) making a mark in the field. Thanks &lt;a href=&#34;https://twitter.com/MLadanyi?ref_src=twsrc%5Etfw&#34;&gt;@MLadanyi&lt;/a&gt; &lt;a href=&#34;https://twitter.com/fsanchezvega?ref_src=twsrc%5Etfw&#34;&gt;@fsanchezvega&lt;/a&gt; &lt;a href=&#34;https://twitter.com/MGZauderer?ref_src=twsrc%5Etfw&#34;&gt;@MGZauderer&lt;/a&gt; for highlighting our work.  &lt;a href=&#34;https://t.co/s1cTVs2TgD&#34;&gt;https://t.co/s1cTVs2TgD&lt;/a&gt; &lt;a href=&#34;https://twitter.com/hashtag/Mesothelioma?src=hash&amp;amp;ref_src=twsrc%5Etfw&#34;&gt;#Mesothelioma&lt;/a&gt; &lt;a href=&#34;https://twitter.com/hashtag/PeritonealMesothelioma?src=hash&amp;amp;ref_src=twsrc%5Etfw&#34;&gt;#PeritonealMesothelioma&lt;/a&gt; &lt;a href=&#34;https://twitter.com/hashtag/Immunotherapy?src=hash&amp;amp;ref_src=twsrc%5Etfw&#34;&gt;#Immunotherapy&lt;/a&gt;&lt;/p&gt;&amp;mdash; Raunak Shrestha (@raunakms) &lt;a href=&#34;https://twitter.com/raunakms/status/1110969391925989377?ref_src=twsrc%5Etfw&#34;&gt;March 27, 2019&lt;/a&gt;&lt;/blockquote&gt;
&lt;script async src=&#34;https://platform.twitter.com/widgets.js&#34; charset=&#34;utf-8&#34;&gt;&lt;/script&gt;
</description>
    </item>
    
  </channel>
</rss>
